Advertisement
ENTX vs JSPR
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ENTX is a StrongBuy and JSPR is a Hold.
ENTX's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for ENTX turned positive on October 16, 2026. Looking at past instances where ENTX's MACD turned positive, the stock continued to rise in 51 of 53 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ENTX's RSI Indicator exited the oversold zone, 28 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on ENTX as a result. In 79 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
ENTX moved above its 50-day moving average on October 27, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ENTX crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 81%.
Following a +8.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where ENTX advanced for three days, in 180 of 230 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
ENTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 87 of 99 cases where ENTX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 88%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 38 of 43 cases where ENTX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ENTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. ENTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 92 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ENTX's P/B Ratio (74.823) is slightly higher than the industry average of (3.498). P/E Ratio (-8.971) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1428.571) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ENTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Momentum Indicator for JSPR turns negative, indicating new downward trend
JSPR saw its Momentum Indicator move below the 0 level on November 10, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 92 similar instances where the indicator turned negative. In 84 of the 92 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JSPR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
JSPR broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for JSPR entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for JSPR just turned positive on October 23, 2026. Looking at past instances where JSPR's MACD turned positive, the stock continued to rise in 32 of 37 cases over the following month. The odds of a continued upward trend are 86%.
Following a +6.61% 3-day Advance, the price is estimated to grow further. Considering data from situations where JSPR advanced for three days, in 203 of 243 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. JSPR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: JSPR's P/B Ratio (397.034) is very high in comparison to the industry average of (3.498). P/E Ratio (-18.129) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. JSPR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
ENTX | JSPR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 35 | 74 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 95 Overvalued | 96 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 99 | 100 | |
PRICE GROWTH RATING 1..100 | 35 | 81 | |
P/E GROWTH RATING 1..100 | 92 | 100 | |
SEASONALITY SCORE 1..100 | n/a | 47 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ENTX's Valuation (95) in the Pharmaceuticals Major industry is in the same range as JSPR (96) in the null industry. This means that ENTX’s stock grew similarly to JSPR’s over the last 12 months.
ENTX's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as JSPR (100) in the null industry. This means that ENTX’s stock grew similarly to JSPR’s over the last 12 months.
ENTX's SMR Rating (99) in the Pharmaceuticals Major industry is in the same range as JSPR (100) in the null industry. This means that ENTX’s stock grew similarly to JSPR’s over the last 12 months.
ENTX's Price Growth Rating (35) in the Pharmaceuticals Major industry is somewhat better than the same rating for JSPR (81) in the null industry. This means that ENTX’s stock grew somewhat faster than JSPR’s over the last 12 months.
ENTX's P/E Growth Rating (92) in the Pharmaceuticals Major industry is in the same range as JSPR (100) in the null industry. This means that ENTX’s stock grew similarly to JSPR’s over the last 12 months.
| ENTX | JSPR | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 82% | N/A |
| Stochastic ODDS (%) | 2 days ago 88% | 2 days ago 89% |
| Momentum ODDS (%) | 2 days ago 83% | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 86% |
| TrendWeek ODDS (%) | 2 days ago 83% | 2 days ago 84% |
| TrendMonth ODDS (%) | 2 days ago 86% | 2 days ago 90% |
| Advances ODDS (%) | 3 days ago 78% | 15 days ago 84% |
| Declines ODDS (%) | 9 days ago 89% | 2 days ago 90% |
| BollingerBands ODDS (%) | 7 days ago 89% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 88% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ENTX’s FA Score shows that 0 FA rating(s) are green while JSPR’s FA Score has 0 green FA rating(s).
- ENTX’s FA Score: 0 green, 5 red.
- JSPR’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ENTX’s TA Score shows that 8 TA indicator(s) are bullish while JSPR’s TA Score has 2 bullish TA indicator(s).
- ENTX’s TA Score: 8 bullish, 2 bearish.
- JSPR’s TA Score: 2 bullish, 5 bearish.
Price Growth
ENTX (@Biotechnology) experienced а +6.23% price change this week, while JSPR (@Biotechnology) price change was +2.43% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
ENTX is expected to report earnings on Mar 26, 2027.
JSPR is expected to report earnings on Mar 09, 2027.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ENTX and
Correlation & Price change
A.I.dvisor tells us that ENTX and JSPR have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ENTX and JSPR's prices will move in lockstep.
| Ticker / NAME | Correlation To ENTX | 1D Price Change % | ||
|---|---|---|---|---|
| ENTX | 100% | -0.31% | ||
| JSPR - ENTX | 32% Poorly correlated | -9.90% | ||
| MLTX - ENTX | 30% Poorly correlated | -0.48% | ||
| QCLS - ENTX | 26% Poorly correlated | -6.52% | ||
| NTLA - ENTX | 26% Poorly correlated | -7.76% | ||
| LGVN - ENTX | 25% Poorly correlated | +41.29% | ||
More | ||||